Vincent Castonguay

2.1k total citations · 2 hit papers
43 papers, 1.0k citations indexed

About

Vincent Castonguay is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Vincent Castonguay has authored 43 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 14 papers in Obstetrics and Gynecology. Recurrent topics in Vincent Castonguay's work include Renal cell carcinoma treatment (17 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Endometrial and Cervical Cancer Treatments (14 papers). Vincent Castonguay is often cited by papers focused on Renal cell carcinoma treatment (17 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Endometrial and Cervical Cancer Treatments (14 papers). Vincent Castonguay collaborates with scholars based in Canada, United States and Italy. Vincent Castonguay's co-authors include Vanessa Samouëlian, Ronnie Shapira‐Frommer, Pamela Salman, Mivael Olivera, Coraline Dubot, Kan Li, Krishnansu S. Tewari, Kosei Hasegawa, Bradley J. Monk and Domenica Lorusso and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Vincent Castonguay

38 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

2021 581 citations Nicoletta Colombo, Coraline Dubot et al. profile →
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

2023 100 citations Bradley J. Monk, Nicoletta Colombo et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Vincent Castonguay

Since Specialization

Citations

This map shows the geographic impact of Vincent Castonguay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Castonguay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Castonguay more than expected).

Fields of papers citing papers by Vincent Castonguay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent Castonguay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Castonguay. The network helps show where Vincent Castonguay may publish in the future.

Co-authorship network of co-authors of Vincent Castonguay

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent Castonguay. A scholar is included among the top collaborators of Vincent Castonguay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent Castonguay. Vincent Castonguay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma 2025 ·The Oncologist ·(unknown), Zineb Hamilou, Sunita Ghosh, Daniel Yick Chin Heng, Lori Wood, Naveen S. Basappa, Christian Kollmannsberger, Jeffrey Graham, Bimal Bhindi, Antonio Finelli, Georg A. Bjarnason, Dominick Bossé, Frédéric Pouliot, Vincent Castonguay, Rodney H. Breau, Ramy Saleh, Eric Winquist, Aly‐Khan A. Lalani, Denis Soulières	1
2	Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study 2025 ·Clinical Genitourinary Cancer ·(unknown), Simon Tanguay, Lori Wood, C. Kollmannsberger, Naveen S. Basappa, (unknown), Denis Soulières, Antonio Finelli, Daniel Y.C. Heng, Vincent Castonguay, Christina Canil, Eric Winquist, Jeffrey Graham, Georg A. Bjarnason, Bimal Bhindi, Aly‐Khan A. Lalani, Frédéric Pouliot, Rodney H. Breau, Ramy Saleh, Alice Dragomir	1
3	Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer 2025 ·BMC Cancer ·(unknown), Michèle Rouleau, Laurent Villeneuve, (unknown), Patrick Caron, (unknown), (unknown), David Simonyan, (unknown), Charles Joly-Beauparlant, (unknown), Arnaud Droit, (unknown), Vincent Castonguay, Louis Lacombe, Éric Lévesque, Chantal Guillemette	0
4	ACCEL: [Ac-225]-PSMA-62 phase Ia/Ib/II clinical trial to characterize efficacy, safety, tolerability, and dosimetry in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer. 2025 ·Journal of Clinical Oncology ·Ramy Saleh, Kim N., (unknown), Vincent Castonguay, (unknown), Ur Metser, Don Wilson, Junsheng Ma, (unknown), (unknown), Jean‐Mathieu Beauregard	0
5	Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study 2024 ·Current Oncology ·(unknown), (unknown), (unknown), Éric Lévesque, (unknown), (unknown), Alexandra Sebastianelli, (unknown), Marc Lalancette, Marie Plante, (unknown), Vincent Castonguay	1
6	Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study 2024 ·Annals of Oncology ·(unknown), Nicoletta Colombo, Coraline Dubot, (unknown), Kazuki Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, (unknown), Ka Wan Li, (unknown), (unknown), Krishnansu S. Tewari, (unknown)	9
7	Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis) 2024 ·Clinical Genitourinary Cancer ·Jeffrey Graham, Sunita Ghosh, Rodney H. Breau, Lori Wood, Simon Tanguay, Dominick Bossé, Aly‐Khan A. Lalani, Bimal Bhindi, Daniel Yick Chin Heng, Antonio Finelli, Nazanin Fallah‐Rad, Vincent Castonguay, Naveen S. Basappa, Denis Soulières, Frédéric Pouliot, Christian Kollmannsberger, Georg A. Bjarnason	0
8	Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database 2024 ·Current Oncology ·(unknown), (unknown), Sunita Ghosh, Lori Wood, Georg A. Bjarnason, Bimal Bhindi, Daniel Yick Chin Heng, Vincent Castonguay, Frédéric Pouliot, Christian Kollmannsberger, Dominick Bossé, Naveen S. Basappa, Antonio Finelli, Nazanin Fallah‐Rad, Rodney H. Breau, Aly‐Khan A. Lalani, Simon Tanguay, Jeffrey Graham, Ramy Saleh	3
9	#67 Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826 2023 ·Domenica Lorusso, Nicoletta Colombo, Bradley J. Monk, Coraline Dubot, (unknown), Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, (unknown), Kan Li, Sarper Toker, Cumhur Tekin, Krishnansu S. Tewari	3
10	Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System 2023 ·JCO Global Oncology ·(unknown), Sunita Ghosh, Antonio Finelli, Lori Wood, Christian Kollmannsberger, Naveen S. Basappa, Jeffrey Graham, Daniel Y.C. Heng, Georg A. Bjarnason, Denis Soulières, Dominick Bossé, Vincent Castonguay, Ramy Saleh, Simon Tanguay, Bimal Bhindi, Rodney H. Breau, Frédéric Pouliot, Aly‐Khan A. Lalani	1
11	First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826 breakdown → 2023 ·Journal of Clinical Oncology ·Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari, Coraline Dubot, (unknown), Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, (unknown), Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, А. В. Архипов, Cumhur Tekin, Kan Li, Stephen J. O’Keefe, Domenica Lorusso, (unknown)	100
12	#1121 KEYNOTE-826: final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer 2023 ·Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, Eduardo Yáñez, Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, А. В. Архипов, Cumhur Tekin, Kan Li, Stephen J. O’Keefe, Domenica Lorusso	2
13	Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 2023 ·The Lancet Oncology ·Bradley J. Monk, Krishnansu S. Tewari, Coraline Dubot, M. Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Pamela Salman, (unknown), Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, Arkhipov Alexander, Cumhur Tekin, Kan Li, Allison Martin Nguyen, Matthew Monberg, Nicoletta Colombo, Domenica Lorusso	37
14	Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies 2023 ·European Urology Oncology ·(unknown), Alice Dragomir, Lori Wood, Christian Kollmannsberger, Naveen S. Basappa, Anil Kapoor, Denis Soulières, Antonio Finelli, Daniel Y.C. Heng, Vincent Castonguay, Christina Canil, Eric Winquist, Jeffrey Graham, Georg A. Bjarnason, Bimal Bhindi, Aly‐Khan A. Lalani, Frédéric Pouliot, Rodney H. Breau, Ramy Saleh, Simon Tanguay	5
15	Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer 2022 ·Obstetrical & Gynecological Survey ·Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, (unknown), Kosei Hasegawa, Ronnie Shapira‐Frommer, Krishnansu S. Tewari, Pamela Salman, (unknown), (unknown), Mahmut Gümüş, Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, Arkhipov Alexander, Sarper Toker, Kan Li, Stephen J. O’Keefe, Bradley J. Monk	10
16	Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients 2021 ·Clinical Genitourinary Cancer ·(unknown), Naveen S. Basappa, Sunita Ghosh, Christian Kollmannsberger, Daniel Y.C. Heng, Aaron R. Hansen, (unknown), Denis Soulières, M. Neil Reaume, Aly‐Khan A. Lalani, Vincent Castonguay, Georg A. Bjarnason, François Patenaude, Rodney H. Breau, Frédéric Pouliot, Anil Kapoor, Lori Wood	6
17	Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis) 2021 ·Han‐Bo Zhang, Naveen S. Basappa, Sunita Ghosh, (unknown), Aly‐Khan A. Lalani, Aaron R. Hansen, Daniel Y.C. Heng, Vincent Castonguay, Christian Kollmannsberger, Eric Winquist, Lori Wood, Georg A. Bjarnason, Rodney H. Breau, Anil Kapoor, Jeffrey Graham	4
18	LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study 2021 ·Annals of Oncology ·Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, (unknown), Kosei Hasegawa, Ronnie Shapira‐Frommer, Krishnansu S. Tewari, Pamela Salman, Eduardo Aguayo de Hoyos, Eduardo Yáñez, (unknown), Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, (unknown), (unknown), Ka Wan Li, Stephen J. O’Keefe, B.J. Monk	4
19	A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia 2014 ·Gynecologic Oncology ·Vincent Castonguay, Stéphanie Lheureux, Stephen Welch, Helen Mackay, Hal W. Hirte, Gini F. Fleming, R.J. Morgan, Lisa Wang, (unknown), Percy Ivy, Amit M. Oza	43
20	ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer 2012 ·European Journal of Cancer ·Ursula A. Matulonis, Julie Lee, (unknown), William P. Tew, (unknown), Daniela Matei, Kian Behbakht, (unknown), Gini F. Fleming, Nita K. Lee, Jamie Arnott, Mark R. Bray, Graham C. Fletcher, Richard D. Brokx, Vincent Castonguay, Helen Mackay, Carolyn Sidor, Amit M. Oza	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact